An update on the clinical approach to giant cell arteritis.
Piccus, Rachel Hansen, Michael Stormly Hamann, Steffen Mollan, Susan P
Piccus, Rachel
Hansen, Michael Stormly
Hamann, Steffen
Mollan, Susan P
Abstract
Recent national and international guidance from rheumatology societies have reflected the advances in evidence for both the investigation and management of giant cell arteritis. Cranial ultrasound reduces diagnostic delay and improves clinical outcomes. Immediate high-dose glucocorticoids remain the standard treatment for giant cell arteritis. Randomised controlled trial evidence using tocilizumab, an interleukin-6 receptor antagonist, has been shown to have good clinical efficacy with glucocorticoid sparing effects. Overall patient outcomes appear to be improved by formalising pathways for diagnosis to include clinical experts' opinion early in decision making.
MIDER Authors
Citations
Altmetric:
Date
2022-03
Type
Article
Subject
Collections
Citation
Piccus R, Hansen MS, Hamann S, Mollan SP. An update on the clinical approach to giant cell arteritis. Clin Med (Lond). 2022 Mar;22(2):107-111. doi: 10.7861/clinmed.2022-0041
Journal / Source Title
Clinical Medicine
DOI
10.7861/clinmed.2022-0041
PMID
35304369
Publisher
Elsevier
Publisher’s URL
https://www.rcpjournals.org/content/clinical-medicine-scope